Epigenetic Therapy for Friedreich ataxia

Annals of Neurology

Volumn 76, Issue 4, 2014, Pages 489-508

  Soragni, Elisabetta ^a   Miao, Wenyan ^b   Iudicello, Marco ^c   Jacoby, David ^b,f   De Mercanti, Stefania ^c   Clerico, Marinella ^c   Longo, Filomena ^d   Piga, Antonio ^d   Ku, Sherman ^a   Campau, Erica ^a   Du, Jintang ^a   Penalver, Pablo ^a,g   Rai, Myriam ^e   Madara, Joseph C ^a   Nazor, Kristopher ^a   O'Connor, Melinda ^b   Maximov, Anton ^a   Loring, Jeanne F ^a   Pandolfo, Massimo ^e   Durelli, Luca ^e   Gottesfeld, Joel M ^a   Rusche, James R ^b   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b REPLIGEN CORPORATION   (United States)

^c SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e FREE UNIVERSITY OF BRUSSELS   (Belgium)

^f BIOMARIN PHARMACEUTICAL INC   (United States)

^g UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; FRATAXIN; HISTONE DEACETYLASE INHIBITOR; IRON BINDING PROTEIN; NERVE PROTEIN; RG2833;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA METHYLATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; FRIEDREICH ATAXIA; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MEMBRANE POTENTIAL; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NERVE CELL; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; PLURIPOTENT STEM CELL; RANDOMIZED CONTROLLED TRIAL; TRANSFORMED CELL LINE; TRINUCLEOTIDE REPEAT; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMINOCAPROATES; AREA UNDER CURVE; BENZAMIDES; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CHROMATIN IMMUNOPRECIPITATION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FRIEDREICH ATAXIA; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; IRON-BINDING PROTEINS; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE POTENTIALS; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; PLURIPOTENT STEM CELLS; TRINUCLEOTIDE REPEAT EXPANSION; YOUNG ADULT;

EID: 84907815534     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24260     Document Type: Article

References (53)

1. Pandolfo M. Friedreich ataxia. Arch Neurol 2008;65:1296-1303.
2. Lynch DR, Farmer JM, Wilson RB. Mortality in Friedreich's Ataxia. Tex Heart Inst J 2007;34:502-503; author reply 503-504.
3. Cnop M, Igoillo-Esteve M, Rai M, et al. Central role and mechanisms of beta-cell dysfunction and death in Friedreich ataxia-associated diabetes. Ann Neurol 2012;72:971-982.
4. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
5. Saveliev A, Everett C, Sharpe T, et al. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 2003;422:909-913.
6. Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006;2:551-558.
7. Greene E, Mahishi L, Entezam A, et al. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucl Acids Res 2007;35:3383-3390.
8. Al-Mahdawi S, Pinto RM, Ismail O, et al. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 2008;17:735-746.
9. Chan PK, Torres R, Yandim C, et al. Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum Mol Genet 2013;22:2662-2675.
10. Pastore A, Puccio H. Frataxin: a protein in search for a function. J Neurochem 2013;126(suppl 1):43-52.
11. Gonzalez-Cabo P, Palau F. Mitochondrial pathophysiology in Friedreich's ataxia. J Neurochem 2013;126(suppl 1):53-64.
12. Libri V, Yandim C, Athanasopoulos S, et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet 2014;384:504-513.
13. Rai M, Soragni E, Chou CJ, et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 2010;5:e8825.
14. Coppola G, Burnett R, Perlman S, et al. A gene expression phenotype in lymphocytes from Friedreich ataxia patients. Ann Neurol 2011;70:790-804.
15. Plasterer HL, Deutsch EC, Belmonte M, et al. Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia. PLoS One 2013;8:e63958.
16. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 2008;3:e1958.
17. Sandi C, Pinto RM, Al-Mahdawi S, et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis 2011;42:496-505.
18. Marchetto MC, Brennand KJ, Boyer LF, Gage FH. Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. Hum Mol Genet 2011;20:R109-R115.
19. Bellin M, Marchetto MC, Gage FH, Mummery CL. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 2012;13:713-726.
20. Ku S, Soragni E, Campau E, et al. Friedreich's ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. Cell Stem Cell 2010;7:631-637.
21. Du J, Campau E, Soragni E, et al. Role of mismatch repair enzymes in GAA.TTC triplet-repeat expansion in Friedreich ataxia induced pluripotent stem cells. J Biol Chem 2012;287:29861-29872.
22. Soragni E, Xu C, Cooper A, et al. Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases. Methods Mol Biol 2011;793:495-508.
23. Soragni E, Herman D, Dent SY, et al. Long intronic GAA∗TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia. Nucleic Acids Res 2008;36:6056-6065.
24. Dottori M, Pera MF. Neural differentiation of human embryonic stem cells. Methods Mol Biol 2008;438:19-30.
25. Hick A, Wattenhofer-Donze M, Chintawar S, et al. Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia. Dis Model Mech 2013;6:608-621.
26. Xu C, Soragni E, Chou CJ, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol 2009;16:980-989.
27. Jia H, Pallos J, Jacques V, et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis 2012;46:351-361.
28. Malvaez M, McQuown SC, Rogge GA, et al. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A 2013;110:2647-2652.
29. Chou CJ, Herman D, Gottesfeld JM. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 2008;283:35402-35409.
30. Lin Y, Dion V, Wilson JH. Transcription promotes contraction of CAG repeat tracts in human cells. Nat Struct Mol Biol 2006;13:179-180.
31. Ditch S, Sammarco MC, Banerjee A, Grabczyk E. Progressive GAA.TTC repeat expansion in human cell lines. PLoS Genet 2009;5:e1000704.
32. Goula AV, Stys A, Chan JP, et al. Transcription elongation and tissue-specific somatic CAG instability. PLoS Genet 2012;8:e1003051.
33. Nakamori M, Pearson CE, Thornton CA. Bidirectional transcription stimulates expansion and contraction of expanded (CTG)∗(CAG) repeats. Hum Mol Genet 2011;20:580-588.
34. Zoghbi HY, Orr HT. Trinucleotide repeat disorders. Ann Rev Neurosci 2007;30:575-621.
35. Bidichandani SI, Ashizawa T, Patel PI. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 1998;62:111-121.
36. Li K, Besse EK, Ha D, et al. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum Mol Genet 2008;17:2265-2273.
37. Qiang L, Fujita R, Abeliovich A. Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders. Neuron 2013;78:957-969.
38. Menendez L, Yatskievych TA, Antin PB, Dalton S. Wnt signaling and a Smad pathway blockade direct the differentiation of human pluripotent stem cells to multipotent neural crest cells. Proc Natl Acad Sci U S A 2011;108:19240-19245.
39. Chambers SM, Qi Y, Mica Y, et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat Biotechnol 2012;30:715-720.
40. Eigentler A, Boesch S, Schneider R, et al.Induced pluripotent stem cells from Friedreich ataxia patients fail to upregulate frataxin during in vitro differentiation to peripheral sensory neurons. Stem Cells Dev 2013;22:3271-3282.
41. Garcia-Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet 2010;19:R83-R89.
42. Klein AF, Gasnier E, Furling D. Gain of RNA function in pathological cases: focus on myotonic dystrophy. Biochimie 2011;93:2006-2012.
43. Soragni E, Xu C, Plasterer HL, et al. Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. J Child Neurol 2012;27:1164-1173.
44. Xu C, Soragni E, Jacques V, et al. Improved histone deacetylase inhibitors as therapeutics for the neurodegenerative disease Friedreich's ataxia: a new synthetic route. Pharmaceuticals 2011;4:1578-1590.
45. Beconi M, Aziz O, Matthews K, et al. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. PLoS One 2012;7:e44498.
46. Yao X, Anderson DL, Ross SA, et al. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br J Pharmacol 2008;154:1446-1456.
47. Lynch DR, Fischbeck KH. Nicotinamide in Friedreich's ataxia: useful or not? Lancet 2014;384:474-475.
48. Burk K, Schulz SR, Schulz JB. Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J Neurochem 2013;126(suppl 1):118-124.
49. Ebert AD, Yu J, Rose FF, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2008;457:277-280.
50. Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012;4:145ra104.
51. Cooper O, Seo H, Andrabi S, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 2012;4:141ra190.
52. Lee G, Ramirez CN, Kim H, et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 2012;30:1244-1248.
53. Xu X, Lei Y, Luo J, et al. Prevention of beta-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of cyclin-dependent kinases and associated cell cycle events. Stem Cell Res 2013;10:213-227.